NeuroCytonix Inc. Email Format
Biotechnology ResearchMaryland, United States11-50 Employees
NeuroCytonix Inc. is a biotechnology research company based in Rockville, Maryland, founded in January 2017 with a focus on developing technologies intended to support the regeneration of the nervous system. The firm describes its work as pursuing first-in-class approaches for treating incurable or non-degenerative neurological conditions, including cerebral palsy, stroke, traumatic brain injury–related consequences, and Covid-19–related neurological issues. The organization operates within the biotechnology research industry and positions itself as advancing disruptive medical technologies for neurological regeneration. Based in the United States, the company has a regional footprint in Rockville and has communicated strategic activities through related entities and collaborations. Recent developments include the launch of a NeuroCytotron protocol for autism through NeuroCytonix Bahamas Ltd and the initiation of a clinical trial in that program, representing a concrete advancement in its research agenda. The company has also announced leadership and strategic partnerships through affiliate entities, reflecting its ongoing efforts to progress its clinical and research activities in non-progressive brain disorders and related areas. NeuroCytonix reports a focus on partnerships with cerebral palsy organizations and FDA-supervised trial activities, underscoring its engagement with clinical development and research collaborators.